Trial Profile
The effect of intravitreal ranibizumab on systemic hypertension in age-related macular degeneration patients with hypertension.
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 04 Nov 2015
Price :
$35
*
At a glance
- Drugs Ranibizumab (Primary)
- Indications Age-related macular degeneration
- Focus Pharmacodynamics
- 18 Mar 2014 New trial record